Literature DB >> 24353117

Time of effect duration and administration interval for sitagliptin in patients with kidney failure.

Frieder Keller1, Bertram Hartmann, David Czock.   

Abstract

A measure correlating the time course of the effect with the time course of concentrations could be helpful in drug dosing. We propose a new equation with explicit solutions for calculating the effect duration. A specific effect fraction is selected (fr) and the time of fractional effect duration (TED.fr) can be derived as a function of the elimination half-life by combining linear elimination kinetics with sigmoid effect dynamics. This new measure is applied to the example of sitagliptin, whose elimination half-life increases from 10.1 to 28.4 h in patients with kidney failure. Under normal multiple-dose conditions, the 24-h sitagliptin administration interval corresponds to a 0.90 time of fractional effect duration (TED.90). A dose reduction to one-fourth or 25 mg every 24 h is proposed for patients with kidney failure; this results in a TED.90 of 45 h, i.e. 21 h longer than the proposed 24-h administration interval (+88 %). The proportional dosing alternative of 100 mg every 96 h would result in a TED.90 of 64 h, which is 32 h less than the 96-h administration interval (-33 %). With a half dose of 50 mg and a doubled administration interval of 48 h, the TED.90 is 51 h in kidney failure, only 3 h longer than the latter administration interval (+6 %). We conclude that our general equation can be applied to rapidly calculate the specific time of effect duration for the different dose schedules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24353117     DOI: 10.1007/s13318-013-0164-7

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  25 in total

1.  Pharmacodynamic half-life and effect-time course in renal impairment.

Authors:  F Keller; D Czock
Journal:  Nephrol Dial Transplant       Date:  1999       Impact factor: 5.992

2.  Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

Authors:  Yasuhiko Iwamoto; Tadaaki Taniguchi; Kenji Nonaka; Taro Okamoto; Kotoba Okuyama; Juan Camilo Arjona Ferreira; John Amatruda
Journal:  Endocr J       Date:  2010-03-24       Impact factor: 2.349

3.  Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

Authors:  Gary A Herman; Goutam C Mistry; Bingming Yi; Arthur J Bergman; Amy Q Wang; Wei Zeng; Li Chen; Karen Snyder; Jon L Ruckle; Patrick J Larson; Michael J Davies; Ronald B Langdon; Keith M Gottesdiener; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

4.  Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

Authors:  Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

5.  On the accuracy of a one-compartment approach for determination of drug terminal half-life.

Authors:  Leonid M Berezhkovskiy
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

6.  Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.

Authors:  F Keller; D Czock; D Zellner; M Giehl
Journal:  Int J Clin Pharmacol Ther       Date:  1998-03       Impact factor: 1.366

7.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

Review 8.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

9.  Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

Authors:  J C N Chan; R Scott; J C Arjona Ferreira; D Sheng; E Gonzalez; M J Davies; P P Stein; K D Kaufman; J M Amatruda; D Williams-Herman
Journal:  Diabetes Obes Metab       Date:  2008-06-01       Impact factor: 6.577

10.  The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms.

Authors:  Selma Sahin; Leslie Z Benet
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

View more
  3 in total

Review 1.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 2.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

3.  Clinical Pharmacodynamics: Principles of Drug Response and Alterations in Kidney Disease.

Authors:  Frieder Keller; Alexander Hann
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-16       Impact factor: 8.237

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.